BLUEHOLE-NEW-CONSUMPTION
29.3.2022 04:15:10 CEST | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on SMOORE‘s establishment of the world’s first E&L testing laboratory in the vaping industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005929/en/
Here below is the full article:
SMOORE, a global leader in offering vaping technology solutions, today announced the establishment of the world’s first extractable and leachable (E&L) testing laboratory in the vaping industry.
Built in the last half of 2021, this laboratory conducts qualitative and quantitative analytical testing and health risk assessment of E&L substances of electronic atomization components, including metals, plastics and other polymers.
As China’s first electronic atomization company to develop a PMTA (Premarket Tobacco Product Applications)-compliant assessment system, including physical tests, chemical tests, non-clinical testing and health risk assessment, SMOORE also set up this E&L testing laboratory based on PMTA safety requirements.
Moreover, SMOORE's E&L testing laboratory is in collaboration with SMITHERS, a world-leading provider of testing, consulting, information, and compliance services. For years, the two companies have worked closely on PMTA compliance.
Currently, most companies in the vaping industry rely on third-party laboratories for E&L testing while SMOORE has set up an in-house laboratory with comprehensive and advanced testing equipment. It follows the analytical methodology of the world’s leading E&L testing laboratories for medical devices.
As SMOORE’s flagship atomization tech brand, FEELM is able to make full use of SMOORE’s world-class testing and risk assessment system, including this E&L testing laboratory. Since 2021, FEELM has leveraged the laboratory for the safety assessment of its electronic atomization components, to guarantee the quality and reliability of FEELM's new products.
In October 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK has planned to integrate medicinally licensed e-cigarettes into the National Health Service (NHS). Other countries, including Australia, have also prescribed adult smokers e-cigarettes to reduce smoking rates. As global regulators started embracing e-cigarettes, they are setting higher safety requirements for e-cigarettes, and SMOORE takes the lead to improve the material reliability of e-cigarettes to medical grade.
E&L analytical testing is widely used in the field of pharmaceutical research and development. The E&L compounds of the packaging materials of pharmaceutical products must be tested before launch, to ensure the product safety compliance.
SMOORE's E&L testing laboratory can provide safety assessment for not only e-cigarettes but also electronic atomization products in other sectors. With one of its R&D focus on the application of atomization technology in healthcare and pharmaceutical fields, SMOORE could leverage this laboratory for the development of healthcare atomization innovations.
"The safety of electronic atomization products primarily depends on the chemical composition of e-liquid and the vapor generated by e-liquid atomization, as well as the E&L substances of other materials in contact with human bodies", said Dr. Long, Director of Analytical Testing and Safety Assessment of SMOORE Fundamental Research Center. "Our E&L testing laboratory specializes in the latter."
According to Dr. Long, SMOORE Fundamental Research Center plans to establish and complete a database of E&L substances in electronic atomization components, and will adopt the principle of Good Laboratory Practice (GLP) to ensure the quality and integrity of test data related to non-clinical safety studies. Meanwhile, SMOORE Fundamental Research Center is also looking for partnership with more Chinese medical device providers on E&L testing.
Since 2020, SMOORE has established its own safety standards, SMOORE 3.0, in accordance with the risk assessment guidance of U.S. EPA (Environmental Protection Agency). Above the safety requirements of the Tobacco Products Directive (TPD) of the EU and AFNOR of France, SMOORE 3.0 covers all of the PMTA tests, including both material safety and vapor safety.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/49078
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
